| Direct Visualization of Antigen-specific CD8+T Cells during the Primary Immune Response to Epstein-Barr Virus In Vivo MFC Callan, L Tan, N Annels, GS Ogg, JDK Wilson, CA O'callaghan, ... The Journal of experimental medicine 187 (9), 1395-1402, 1998 | 1126 | 1998 |
| A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor JCC Hu, RS Coffin, CJ Davis, NJ Graham, N Groves, PJ Guest, ... Clinical cancer research 12 (22), 6737-6747, 2006 | 667 | 2006 |
| A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma DH Palmer, RS Midgley, N Mirza, EE Torr, F Ahmed, JC Steele, ... Hepatology 49 (1), 124-132, 2009 | 651 | 2009 |
| Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state RJ Tierney, N Steven, LS Young, AB Rickinson Journal of virology 68 (11), 7374-7385, 1994 | 604 | 1994 |
| Large clonal expansions of CD8+ T cells in acute infectious mononucleosis MFC Callan, N Steven, P Krausa, JDK Wilson, PAH Moss, GM Gillespie, ... Nature medicine 2 (8), 906-911, 1996 | 575 | 1996 |
| Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas M Cullen, N Steven, L Billingham, C Gaunt, M Hastings, P Simmonds, ... New England Journal of Medicine 353 (10), 988-998, 2005 | 482 | 2005 |
| Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus–induced cytotoxic T cell response NM Steven, NE Annels, A Kumar, AM Leese, MG Kurilla, AB Rickinson The Journal of experimental medicine 185 (9), 1605-1618, 1997 | 425 | 1997 |
| Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)–containing protein requires exogenous processing N Blake, S Lee, I Redchenko, W Thomas, N Steven, A Leese, ... Immunity 7 (6), 791-802, 1997 | 327 | 1997 |
| A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors E Angevin, J Tabernero, E Elez, SJ Cohen, R Bahleda, JL Van Laethem, ... Clinical Cancer Research 20 (8), 2192-2204, 2014 | 239 | 2014 |
| Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. NM Steven, AM Leese, NE Annels, SP Lee, AB Rickinson The Journal of experimental medicine 184 (5), 1801-1813, 1996 | 220 | 1996 |
| Phase I trial of recombinant modified vaccinia ankara encoding Epstein–Barr viral tumor antigens in nasopharyngeal carcinoma patients EP Hui, GS Taylor, H Jia, BBY Ma, SL Chan, R Ho, WL Wong, S Wilson, ... Cancer research 73 (6), 1676-1688, 2013 | 208 | 2013 |
| A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation R Plummer, P Lorigan, N Steven, L Scott, MR Middleton, RH Wilson, ... Cancer chemotherapy and pharmacology 71, 1191-1199, 2013 | 206 | 2013 |
| A recombinant modified vaccinia ankara vaccine encoding Epstein–Barr virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer GS Taylor, H Jia, K Harrington, LW Lee, J Turner, K Ladell, DA Price, ... Clinical Cancer Research 20 (19), 5009-5022, 2014 | 189 | 2014 |
| Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma MR Middleton, C McAlpine, VK Woodcock, P Corrie, JR Infante, ... Clinical Cancer Research 26 (22), 5869-5878, 2020 | 183 | 2020 |
| Dual Stimulation of Epstein-Barr Virus (EBV)-Specific CD4+- and CD8+-T-Cell Responses by a Chimeric Antigen Construct: Potential Therapeutic Vaccine for EBV … GS Taylor, TA Haigh, NH Gudgeon, RJ Phelps, SP Lee, NM Steven, ... Journal of virology 78 (2), 768-778, 2004 | 162 | 2004 |
| A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation L Rees, EJ Tizard, AJ Morgan, WD Cubitt, S Finerty, TA Oyewole-Eletu, ... Transplantation 88 (8), 1025-1029, 2009 | 154 | 2009 |
| Research methods to change clinical practice for patients with rare cancers L Billingham, K Malottki, N Steven The Lancet Oncology 17 (2), e70-e80, 2016 | 125 | 2016 |
| Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study P Johnson, R Challis, F Chowdhury, Y Gao, M Harvey, T Geldart, P Kerr, ... Clinical Cancer Research 21 (6), 1321-1328, 2015 | 121 | 2015 |
| The use of herbal medicines by people with cancer: a qualitative study C Gratus, S Wilson, SM Greenfield, SL Damery, SA Warmington, R Grieve, ... BMC Complementary and Alternative Medicine 9, 1-7, 2009 | 120 | 2009 |
| First and final report of a phase II study of the poly (ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic … R Plummer, P Lorigan, J Evans, N Steven, M Middleton, R Wilson, ... Journal of Clinical Oncology 24 (18_suppl), 8013-8013, 2006 | 119 | 2006 |
